Frank Clyburn Biography and Net Worth

EVP of Merck & Co., Inc.

Frank Clyburn is executive vice president and president of Human Health for Merck. He is responsible for all Human Health marketing and commercial operations globally and the P&L for the company’s portfolio of medicines and vaccines.

Prior to this role, Frank was chief commercial officer for Merck, responsible for Human Health commercial operations and the Human Health P&L. From 2013 to 2018, Frank was the inaugural president of the company’s global oncology business. He led the creation of this fully integrated global business unit, the worldwide launch of Merck’s immuno-oncology medicine and the establishment of Merck as a leader in oncology.

Previously, he was the president of the primary care and women’s health businesses and market access function. He also led the company’s global pharmaceutical franchises and lived in Shanghai and Lucerne. Frank joined the company in 2008 to lead its biologics business.

Before joining Merck, Frank was vice president of the oncology and internal medicine business units at Sanofi Aventis and held a wide range of leadership roles with that company, in addition to leading the integration of Sanofi and Aventis.

Frank received his Master of Business Administration degree from Arizona State University and his Bachelor of Arts degree from Franklin & Marshall College. He currently serves on the board of directors for the European Federation of Pharmaceutical Industries and Associations (EFPIA) and DuPont. Frank also served as chairman to the Thomas Edison State University board of trustees.

What is Frank Clyburn's net worth?: The estimated net worth of Frank Clyburn is at least $8.73 million as of August 5th, 2020. Mr. Clyburn owns 99,639 shares of Merck & Co., Inc. stock worth more than $8,732,561 as of February 21st. This net worth evaluation does not reflect any other assets that Mr. Clyburn may own. Learn More about Frank Clyburn's net worth.
How do I contact Frank Clyburn?: The corporate mailing address for Mr. Clyburn and other Merck & Co., Inc. executives is 2000 GALLOPING HILL ROAD, KENILWORTH NJ, 07033. Merck & Co., Inc. can also be reached via phone at (908) 740-4000 and via email at investor_relations@merck.com. Learn More on Frank Clyburn's contact information.
Has Frank Clyburn been buying or selling shares of Merck & Co., Inc.?: Frank Clyburn has not been actively trading shares of Merck & Co., Inc. over the course of the past ninety days. Most recently, Frank Clyburn sold 39,762 shares of the business's stock in a transaction on Monday, November 1st. The shares were sold at an average price of $87.87, for a transaction totalling $3,493,886.94. Learn More on Frank Clyburn's trading history.
Who are Merck & Co., Inc.'s active insiders?: Merck & Co., Inc.'s insider roster includes Sanat Chattopadhyay (Insider), Frank Clyburn (EVP), Robert Davis (CFO), Richard Deluca (EVP), Cristal Downing (Insider), Kenneth Frazier (Insider), Julie Gerberding (EVP), Clark Golestani (EVP), Michael Holston (EVP), Rita Karachun (VP), Caroline Litchfield (CFO), Steven Mizell (EVP), Johannes Oosthuizen (Insider), Joseph Romanelli (Insider), Inge Thulin (Director), Ashley Watson (SVP), and Wendell Weeks (Director). Learn More on Merck & Co., Inc.'s active insiders.
Are insiders buying or selling shares of Merck & Co., Inc.?: During the last year, Merck & Co., Inc. insiders bought shares 1 times. They purchased a total of 2,833 shares worth more than $250,012.25. During the last year, insiders at the sold shares 1 times. They sold a total of 2,361 shares worth more than $209,562.36. The most recent insider tranaction occured on February, 6th when Director Inge G Thulin bought 2,833 shares worth more than $250,012.25. Insiders at Merck & Co., Inc. own 0.1% of the company. Learn More about insider trades at Merck & Co., Inc..
Information on this page was last updated on 2/6/2025.

Frank Clyburn Insider Trading History at Merck & Co., Inc.

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
11/1/2021	Sell	39,762	$87.87	$3,493,886.94
5/10/2021	Sell	19,324	$78.32	$1,513,455.68
8/5/2020	Sell	18,876	$81.55	$1,539,337.80	99,639
5/7/2019	Sell	25,000	$77.73	$1,943,250.00	92,604

Frank Clyburn Buying and Selling Activity at Merck & Co., Inc.

Merck & Co., Inc. Company Overview

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Today's Range

Now: $87.64

$85.90

$87.70

50 Day Range

MA: $95.71

$83.01

$102.00

2 Week Range

Now: $87.64

$81.04

$134.63

Volume

14,834,057 shs

Average Volume

17,607,852 shs

Market Capitalization

$221.70 billion

P/E Ratio

13.02

Dividend Yield

3.79%

Beta

0.38